3 TSX Dividend Aristocrats That Can Protect You From Inflation

Three TSX Dividend Aristocrats are excellent choices for solid protection from high inflation.

| More on:

Dividend stocks help investors earn extra money or passive income. But with inflation at elevated levels, more people should consider owning dividend stocks to hedge against it. Also, should high inflation persist, don’t settle for ordinary dividend payers.

Your best options are Dividend Aristocrats like Emera (TSX:EMA), Algonquin Power & Utilities (TSX:AQN), and Exco Technologies (TSX:XTC). Their dividend payments should continue in the current economic environment.

Defensive asset

Emera is a strong buy if you’re panic-stricken. Besides its defensive nature, the growth profile is intact, if not solid. At $52.31 per share (-14.55% year to date), the dividend yield is a juicy 4.99%. This $13.9 billion energy and services company has raised its dividend for 15 consecutive years and plans to increase the payout by 4-5% annually through 2025.

Scott Balfour, Emera’s president and chief executive officer (CEO), said the dividend-growth guidance reflects management’s confidence in the high-quality regulated utility portfolio. The investments in regulated electricity generation and electricity and gas (transmission and distribution) would drive earnings and cash flow growth.

In the six months ended June 30, 2022, Emera’s net income was steady. It rose 15.2% year over year to $295 million. Balfour added, “Our portfolio of high-quality regulated assets continues to deliver solid performance and predictable earnings growth.”

Growth-oriented renewable firm

Algonquin Power is a top choice in the renewable energy space. The business model of this $9.65 billion is also defensive owing to its rate-regulated utility assets. Moreover, it offers a healthy 6.95% dividend. At $14.24 per share, you can purchase 1,620 shares ($23.068.80 investment) to generate $400.82 in passive income every quarter.

The continued earnings and cash flow growth enabled the utility stock to increase its dividends for 11 consecutive years. Because of strategic acquisitions and the ongoing development of world-class renewables, management expects to see sustainable, rapid growth in the years to come.

In the second quarter (Q2) of 2022, adjusted net earnings reached US$109.7 million, representing a 19.6% increase from Q2 2021. Notably, cash provided by operations soared 160% year over year to US$268.6 million. Consider buying this dividend-growth stock while the price is down 18.89% year to date.

Bright future ahead

Exco Technologies flies under the radar, but it should be valuable to your stock portfolio. The $282.11 million company designs, develops and manufactures dies, moulds, components, assemblies, and consumable equipment for the die-cast, extrusion, and automotive industries. Its diverse and broad customer base is in nine countries.

This small-cap industrial stock boasts a mean dividend-growth streak of 16 years. It trades at $7.25, or at a deep discount (-27.05% year to date). However, the 5.79% dividend should compensate for the stock’s temporary weakness. While sales in Q3 fiscal 2022 increased 12.4% to $129.25 million versus Q3 fiscal 2021, net income dropped 35.9% year over year to $5.56 million.

Still, its president and CEO Darren Kirk said, “Our results demonstrate Exco’s ability to navigate through very challenging market conditions.” He expects Exco to benefit from the electric vehicle revolution and worldwide movement towards reducing emissions.

Solid protection

Investors today need solid protection from high inflation. The dividend-growth streaks and depressed prices of Emera, Algonquin, and Exco are compelling reasons to invest in the Dividend Aristocrats today.  

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends EXCO TECH. The Motley Fool recommends EMERA INCORPORATED. The Motley Fool has a disclosure policy.

More on Dividend Stocks

Concept of multiple streams of income
Dividend Stocks

Passive Income: How Much Do You Need to Invest to Make $400 Per Month?

This fund's fixed $0.10-per-share monthly payout makes passive-income math easy.

Read more »

voice-recognition-talking-to-a-smartphone
Dividend Stocks

How to Turn Losing TSX Telecom Stock Picks Into Tax Savings

Telecom stocks could be a good tax-loss harvesting candidate for year-end.

Read more »

Business success of growth metaverse finance and investment profit graph concept or development analysis progress chart on financial market achievement strategy background with increase hand diagram
Dividend Stocks

2 Dividend Growth Stocks Look Like Standout Buys as the Market Keeps Surging

Enbridge (TSX:ENB) stock and another standout name to watch closely in the new year.

Read more »

a person watches stock market trades
Dividend Stocks

For Passive Income Investing, 3 Canadian Stocks to Buy Right Now

Don't look now, but these three Canadian dividend stocks look poised for some big upside, particularly as interest rates appear…

Read more »

Dividend Stocks

Got $7,000? Where to Invest Your TFSA Contribution in 2026

Putting $7,000 to work in your 2026 TFSA? Consider BMO, Granite REIT, and VXC for steady income, diversification, and long-term…

Read more »

Young adult concentrates on laptop screen
Dividend Stocks

A Beginner’s Guide to Building a Passive Income Portfolio

Are you a new investor looking to earn safe dividends? Here are some tips for a beginner investor who wants…

Read more »

container trucks and cargo planes are part of global logistics system
Dividend Stocks

Before the Clock Strikes Midnight on 2025 – TSX Transportation & Logistics Stocks to Buy

Three TSX stocks are buying opportunities in Canada’s dynamic and rapidly evolving transportation and logistics sector.

Read more »

some REITs give investors exposure to commercial real estate
Dividend Stocks

The Ideal Canadian Stock for Dividends and Growth

Want dividends plus steady growth? Power Corporation offers a “quiet compounder” mix of cash flow today and patient compounding from…

Read more »